共1页/3条首页上一页1下一页尾页
回复:3 阅读:2011
求教有关细支气管肺泡癌的新进展

水晶蔷薇 离线

帖子:454
粉蓝豆:308
经验:1828
注册时间:2011-11-30
加关注  |  发消息
楼主 发表于 2011-12-15 18:33|举报|关注(0)
浏览排序[ 顺序 逆序 楼主 支持 精彩 ]  快捷回复

最近遇到一例,镜下形态考虑细支气管肺泡癌,但因为靠近胸膜,似乎有胸膜的侵犯,请问有胸膜侵犯后,要改报高分化腺癌吗,病人借走切片了,待还片后上传图片 

标签:
0
添加参考诊断
×参考诊断
  

病理020 离线

帖子:1344
粉蓝豆:4645
经验:1814
注册时间:2011-10-02
加关注  |  发消息
1 楼    发表于2011-12-15 19:06:35举报|引用
返回顶部 | 快捷回复

“细支气管肺泡癌”这一名称已经废弃了。

0
回复
signature
邓学田

emilypeaker 离线

帖子:654
粉蓝豆:1570
经验:2182
注册时间:2011-01-03
加关注  |  发消息
2 楼    发表于2011-12-15 19:29:42举报|引用
返回顶部 | 快捷回复
Semin Respir Crit Care Med. 2011 Feb;32(1):52-61. Epub 2011 Apr 15.

Bronchioloalveolar carcinoma.

Source

Division of Pulmonary Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA. darenber@umich.edu

Abstract

This review focuses on aspects of bronchioloalveolar carcinoma (BAC) in which it differs importantly from other forms of non-small-cell lung cancer. BAC is a form of adenocarcinoma with unique clinical, radiological, and epidemiological features. With the notable exception of a lower likelihood of a positive positron-emission tomographic (PET) scan in BAC, staging, diagnosis, and treatment are largely the same as for other histological subtypes of lung cancer. However, additional treatment options exist that are equivalent, if not more effective, for many patients with BAC. The diagnosis of BAC should be reserved for those tumors meeting the 1999/2004 criteria set forth by the World Health Organization. Revised nomenclature proposed by an expert consensus panel may change how this disease is viewed. Additional clinical trials are needed on patients with BAC, employing strict definitions and enrollment criteria to allow the results to be applied to appropriate patient populations.

1

PNET
回复
signature
Suffered from papillary thyroid carcinoma, then major in Endocrine tumor.

emilypeaker 离线

帖子:654
粉蓝豆:1570
经验:2182
注册时间:2011-01-03
加关注  |  发消息
3 楼    发表于2011-12-15 19:38:02举报|引用
返回顶部 | 快捷回复
Cancer Res. 2011 Nov 1;71(21):6665-75. Epub 2011 Sep 12.

Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor.

Source

Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Abstract

Clinical investigations have suggested that repression of the TGF-β type II receptor (TβRII) may be an important step in progression of lung adenocarcinoma from an indolent in situ state to a frank invasive carcinoma. To test this hypothesis, we compared the effects of deleting the murine homolog of this receptor (Tgfbr2) in a mouse model of mutant K-ras-induced lung carcinoma, which normally induces the formation of multifocal tumors of low invasive potential. In this model, loss of Tgfbr2 induced a highly invasive phenotype associated with lymph node metastasis and reduced survival. Tumor-associated stromal cells displayed an immunosuppressive profile marked by increased numbers of B and T cells. Moreover, tumor stromal cell profiling revealed a developmental TGF-β response profile that associated with a collagenized extracellular matrix and increased invasion of TGF-β nonresponsive tumor cells. Together, these results suggest that our KrasTgfbr2(-/-) mouse model of invasive lung carcinoma mirrors the genomic response and clinical progression of human lung adenocarcinoma, recapitulating changes in lung stromal pathways that occur in the tumor microenvironment during malignant progression in this disease.

1

PNET
回复
signature
Suffered from papillary thyroid carcinoma, then major in Endocrine tumor.
回复:3 阅读:2011
共1页/3条首页上一页1下一页尾页
【免责声明】讨论内容仅作学术交流之用,不作为诊疗依据,由此而引起的法律问题作者及本站不承担任何责任。
快速回复
进入高级回复
您最多可输入10000个汉字,按 "Ctrl" + "Enter" 直接发送
搜索回复/乘电梯 ×
按内容
按会员
乘电梯
合作伙伴
友情链接